SEOUL — South Korea’s Drug Ministry said Wednesday it was negotiating with US-based Gilead Sciences for emergency imports of remdesivir, a drug candidate that has shown clinical efficacy in treating COVID-19.
Remdesivir is Gilead Science’s proposed drug candidate for Ebola, which has been circuited to test its effect on the latest coronavirus pandemic.
In a pan-global clinical trial encompassing 73 institutes across 10 nations targeting over 1,000 COVID-19 patients, patients who were given remdesivir recovered 31 percent faster than those who were given placebo. The median number of days to recovery had shortened from 15 days to 11 days.
The ministry said that it decided t…
Keep on reading: S. Korea allows emergency imports of remdesivir